Inflammatory markers and BDNF in obstructive sleep apnea (OSA) in Parkinson's disease (PD)

Obstructive sleep apnea (OSA) exacerbates Parkinson's disease (PD) manifestations including cognitive dysfunction. Both OSA and PD have been associated with inflammation. Brain-derived neurotrophic factor (BDNF) has been implicated in cognitive function. We aimed to investigate inflammatory cyt...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Sleep medicine 2022-02, Vol.90, p.258-261
Hauptverfasser: Kaminska, M., O'Sullivan, M., Mery, V.P., Lafontaine, A.L., Robinson, A., Gros, P., Martin, J.G., Benedetti, A., Kimoff, R.J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 261
container_issue
container_start_page 258
container_title Sleep medicine
container_volume 90
creator Kaminska, M.
O'Sullivan, M.
Mery, V.P.
Lafontaine, A.L.
Robinson, A.
Gros, P.
Martin, J.G.
Benedetti, A.
Kimoff, R.J.
description Obstructive sleep apnea (OSA) exacerbates Parkinson's disease (PD) manifestations including cognitive dysfunction. Both OSA and PD have been associated with inflammation. Brain-derived neurotrophic factor (BDNF) has been implicated in cognitive function. We aimed to investigate inflammatory cytokines and BDNF in relation to OSA and PD symptoms. In a prospective observational study, patients with PD underwent overnight polysomnography. Morning serum levels of interleukin (IL)-1β, IL-6, IL-8, TNFα, and BDNF were quantified at baseline (n = 64) and 6 months (n = 38). Outcomes included non-motor and motor standard scores; Montreal Cognitive Assessment (MoCA); and Epworth Sleepiness scale (ESS). Associations were assessed using linear regression, adjusting for age, sex and body mass index. At baseline, IL-6 was associated with the Apnea–Hypopnea Index (β = 0.013, p = 0.03), and the Oxygen Desaturation Index (β = 0.028, p = 0.002). No other associations between cytokines and sleep parameters were found. Motor dysfunction was associated with IL-6 (β = 0.03, p = 0.001). ESS was associated non-significantly with IL-6 (β = 0.04, p = 0.07) and BDNF (β = 555, p = 0.06). At follow-up, change in IL-6 was associated with change in non-motor (β = 0.08, p = 0.007), and motor (β = 0.03, p = 0.001) symptoms. Change in BDNF was associated with change in ESS (β = 1450, p = 0.02). We found an association between IL-6 levels and both OSA severity and PD motor dysfunction. At follow-up, increasing IL-6 correlated with deterioration of motor and non-motor PD symptoms. Increasing BDNF correlated with increasing sleepiness. Further work with a larger sample size is needed, but our results support the hypothesis that OSA-related inflammation plays a role in PD manifestations and progression. •Interleukin-6 (IL-6) was associated with severity of obstructive sleep apnea (OSA) and of motor dysfunction in individuals with Parkinson's disease (PD).•Deterioration of motor and non-motor symptoms over 6 months was associated with increasing IL-6.•Increasing BDNF was associated with increasing daytime sleepiness.•These data support further work to elucidate the impact of OSA and sleep disturbances overall in PD symptomatology and progression.
doi_str_mv 10.1016/j.sleep.2021.11.018
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2634851778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1389945722000442</els_id><sourcerecordid>2634851778</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-edae0b3f9e40f4c65dea11e5b98866723acdba80cba1fb4d04989f7e51d304233</originalsourceid><addsrcrecordid>eNp9kDtPwzAUhS0E4v0LkJA32iHBN44TZ2Ao5SkhWglYWCzHvpFc8ih2isS_J6XAyGQP37lH5yPkBFgMDLLzRRxqxGWcsARigJiB3CL7IHMZCcGy7eHPZREVqcj3yEEIC8YgB5nukj0ukkQCz_bJ631b1bppdN_5T9po_4Y-UN1aenn1eENdS7sy9H5leveB9LuQ6mWLmo5mT5PxGpgPIdeGrj0L1LqAOiAdza_GR2Sn0nXA45_3kLzcXD9P76KH2e39dPIQGS6KPkKrkZW8KjBlVWoyYVEDoCgLKbMsT7g2ttSSmVJDVaaWpYUsqhwFWM7ShPNDMtrcXfrufYWhV40LButat9itgkoynkoBeS4HlG9Q47sQPFZq6d0w-lMBU2upaqG-N6q1VAWgBqlD6vSnYFU2aP8yvxYH4GID4DDzw6FXwThsDVrn0fTKdu7fgi_FlIhb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2634851778</pqid></control><display><type>article</type><title>Inflammatory markers and BDNF in obstructive sleep apnea (OSA) in Parkinson's disease (PD)</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kaminska, M. ; O'Sullivan, M. ; Mery, V.P. ; Lafontaine, A.L. ; Robinson, A. ; Gros, P. ; Martin, J.G. ; Benedetti, A. ; Kimoff, R.J.</creator><creatorcontrib>Kaminska, M. ; O'Sullivan, M. ; Mery, V.P. ; Lafontaine, A.L. ; Robinson, A. ; Gros, P. ; Martin, J.G. ; Benedetti, A. ; Kimoff, R.J.</creatorcontrib><description>Obstructive sleep apnea (OSA) exacerbates Parkinson's disease (PD) manifestations including cognitive dysfunction. Both OSA and PD have been associated with inflammation. Brain-derived neurotrophic factor (BDNF) has been implicated in cognitive function. We aimed to investigate inflammatory cytokines and BDNF in relation to OSA and PD symptoms. In a prospective observational study, patients with PD underwent overnight polysomnography. Morning serum levels of interleukin (IL)-1β, IL-6, IL-8, TNFα, and BDNF were quantified at baseline (n = 64) and 6 months (n = 38). Outcomes included non-motor and motor standard scores; Montreal Cognitive Assessment (MoCA); and Epworth Sleepiness scale (ESS). Associations were assessed using linear regression, adjusting for age, sex and body mass index. At baseline, IL-6 was associated with the Apnea–Hypopnea Index (β = 0.013, p = 0.03), and the Oxygen Desaturation Index (β = 0.028, p = 0.002). No other associations between cytokines and sleep parameters were found. Motor dysfunction was associated with IL-6 (β = 0.03, p = 0.001). ESS was associated non-significantly with IL-6 (β = 0.04, p = 0.07) and BDNF (β = 555, p = 0.06). At follow-up, change in IL-6 was associated with change in non-motor (β = 0.08, p = 0.007), and motor (β = 0.03, p = 0.001) symptoms. Change in BDNF was associated with change in ESS (β = 1450, p = 0.02). We found an association between IL-6 levels and both OSA severity and PD motor dysfunction. At follow-up, increasing IL-6 correlated with deterioration of motor and non-motor PD symptoms. Increasing BDNF correlated with increasing sleepiness. Further work with a larger sample size is needed, but our results support the hypothesis that OSA-related inflammation plays a role in PD manifestations and progression. •Interleukin-6 (IL-6) was associated with severity of obstructive sleep apnea (OSA) and of motor dysfunction in individuals with Parkinson's disease (PD).•Deterioration of motor and non-motor symptoms over 6 months was associated with increasing IL-6.•Increasing BDNF was associated with increasing daytime sleepiness.•These data support further work to elucidate the impact of OSA and sleep disturbances overall in PD symptomatology and progression.</description><identifier>ISSN: 1389-9457</identifier><identifier>EISSN: 1878-5506</identifier><identifier>DOI: 10.1016/j.sleep.2021.11.018</identifier><identifier>PMID: 35228136</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>BDNF ; Brain-Derived Neurotrophic Factor - blood ; Cognition ; CPAP ; Humans ; Inflammation ; Obstructive sleep apnea ; Parkinson Disease - complications ; Parkinson's disease ; Polysomnography ; Prospective Studies ; Sleep Apnea, Obstructive ; Sleep disorders</subject><ispartof>Sleep medicine, 2022-02, Vol.90, p.258-261</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-edae0b3f9e40f4c65dea11e5b98866723acdba80cba1fb4d04989f7e51d304233</citedby><cites>FETCH-LOGICAL-c359t-edae0b3f9e40f4c65dea11e5b98866723acdba80cba1fb4d04989f7e51d304233</cites><orcidid>0000-0001-8250-5915 ; 0000-0003-2232-173X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1389945722000442$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35228136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaminska, M.</creatorcontrib><creatorcontrib>O'Sullivan, M.</creatorcontrib><creatorcontrib>Mery, V.P.</creatorcontrib><creatorcontrib>Lafontaine, A.L.</creatorcontrib><creatorcontrib>Robinson, A.</creatorcontrib><creatorcontrib>Gros, P.</creatorcontrib><creatorcontrib>Martin, J.G.</creatorcontrib><creatorcontrib>Benedetti, A.</creatorcontrib><creatorcontrib>Kimoff, R.J.</creatorcontrib><title>Inflammatory markers and BDNF in obstructive sleep apnea (OSA) in Parkinson's disease (PD)</title><title>Sleep medicine</title><addtitle>Sleep Med</addtitle><description>Obstructive sleep apnea (OSA) exacerbates Parkinson's disease (PD) manifestations including cognitive dysfunction. Both OSA and PD have been associated with inflammation. Brain-derived neurotrophic factor (BDNF) has been implicated in cognitive function. We aimed to investigate inflammatory cytokines and BDNF in relation to OSA and PD symptoms. In a prospective observational study, patients with PD underwent overnight polysomnography. Morning serum levels of interleukin (IL)-1β, IL-6, IL-8, TNFα, and BDNF were quantified at baseline (n = 64) and 6 months (n = 38). Outcomes included non-motor and motor standard scores; Montreal Cognitive Assessment (MoCA); and Epworth Sleepiness scale (ESS). Associations were assessed using linear regression, adjusting for age, sex and body mass index. At baseline, IL-6 was associated with the Apnea–Hypopnea Index (β = 0.013, p = 0.03), and the Oxygen Desaturation Index (β = 0.028, p = 0.002). No other associations between cytokines and sleep parameters were found. Motor dysfunction was associated with IL-6 (β = 0.03, p = 0.001). ESS was associated non-significantly with IL-6 (β = 0.04, p = 0.07) and BDNF (β = 555, p = 0.06). At follow-up, change in IL-6 was associated with change in non-motor (β = 0.08, p = 0.007), and motor (β = 0.03, p = 0.001) symptoms. Change in BDNF was associated with change in ESS (β = 1450, p = 0.02). We found an association between IL-6 levels and both OSA severity and PD motor dysfunction. At follow-up, increasing IL-6 correlated with deterioration of motor and non-motor PD symptoms. Increasing BDNF correlated with increasing sleepiness. Further work with a larger sample size is needed, but our results support the hypothesis that OSA-related inflammation plays a role in PD manifestations and progression. •Interleukin-6 (IL-6) was associated with severity of obstructive sleep apnea (OSA) and of motor dysfunction in individuals with Parkinson's disease (PD).•Deterioration of motor and non-motor symptoms over 6 months was associated with increasing IL-6.•Increasing BDNF was associated with increasing daytime sleepiness.•These data support further work to elucidate the impact of OSA and sleep disturbances overall in PD symptomatology and progression.</description><subject>BDNF</subject><subject>Brain-Derived Neurotrophic Factor - blood</subject><subject>Cognition</subject><subject>CPAP</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Obstructive sleep apnea</subject><subject>Parkinson Disease - complications</subject><subject>Parkinson's disease</subject><subject>Polysomnography</subject><subject>Prospective Studies</subject><subject>Sleep Apnea, Obstructive</subject><subject>Sleep disorders</subject><issn>1389-9457</issn><issn>1878-5506</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kDtPwzAUhS0E4v0LkJA32iHBN44TZ2Ao5SkhWglYWCzHvpFc8ih2isS_J6XAyGQP37lH5yPkBFgMDLLzRRxqxGWcsARigJiB3CL7IHMZCcGy7eHPZREVqcj3yEEIC8YgB5nukj0ukkQCz_bJ631b1bppdN_5T9po_4Y-UN1aenn1eENdS7sy9H5leveB9LuQ6mWLmo5mT5PxGpgPIdeGrj0L1LqAOiAdza_GR2Sn0nXA45_3kLzcXD9P76KH2e39dPIQGS6KPkKrkZW8KjBlVWoyYVEDoCgLKbMsT7g2ttSSmVJDVaaWpYUsqhwFWM7ShPNDMtrcXfrufYWhV40LButat9itgkoynkoBeS4HlG9Q47sQPFZq6d0w-lMBU2upaqG-N6q1VAWgBqlD6vSnYFU2aP8yvxYH4GID4DDzw6FXwThsDVrn0fTKdu7fgi_FlIhb</recordid><startdate>202202</startdate><enddate>202202</enddate><creator>Kaminska, M.</creator><creator>O'Sullivan, M.</creator><creator>Mery, V.P.</creator><creator>Lafontaine, A.L.</creator><creator>Robinson, A.</creator><creator>Gros, P.</creator><creator>Martin, J.G.</creator><creator>Benedetti, A.</creator><creator>Kimoff, R.J.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8250-5915</orcidid><orcidid>https://orcid.org/0000-0003-2232-173X</orcidid></search><sort><creationdate>202202</creationdate><title>Inflammatory markers and BDNF in obstructive sleep apnea (OSA) in Parkinson's disease (PD)</title><author>Kaminska, M. ; O'Sullivan, M. ; Mery, V.P. ; Lafontaine, A.L. ; Robinson, A. ; Gros, P. ; Martin, J.G. ; Benedetti, A. ; Kimoff, R.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-edae0b3f9e40f4c65dea11e5b98866723acdba80cba1fb4d04989f7e51d304233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>BDNF</topic><topic>Brain-Derived Neurotrophic Factor - blood</topic><topic>Cognition</topic><topic>CPAP</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Obstructive sleep apnea</topic><topic>Parkinson Disease - complications</topic><topic>Parkinson's disease</topic><topic>Polysomnography</topic><topic>Prospective Studies</topic><topic>Sleep Apnea, Obstructive</topic><topic>Sleep disorders</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaminska, M.</creatorcontrib><creatorcontrib>O'Sullivan, M.</creatorcontrib><creatorcontrib>Mery, V.P.</creatorcontrib><creatorcontrib>Lafontaine, A.L.</creatorcontrib><creatorcontrib>Robinson, A.</creatorcontrib><creatorcontrib>Gros, P.</creatorcontrib><creatorcontrib>Martin, J.G.</creatorcontrib><creatorcontrib>Benedetti, A.</creatorcontrib><creatorcontrib>Kimoff, R.J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Sleep medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaminska, M.</au><au>O'Sullivan, M.</au><au>Mery, V.P.</au><au>Lafontaine, A.L.</au><au>Robinson, A.</au><au>Gros, P.</au><au>Martin, J.G.</au><au>Benedetti, A.</au><au>Kimoff, R.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inflammatory markers and BDNF in obstructive sleep apnea (OSA) in Parkinson's disease (PD)</atitle><jtitle>Sleep medicine</jtitle><addtitle>Sleep Med</addtitle><date>2022-02</date><risdate>2022</risdate><volume>90</volume><spage>258</spage><epage>261</epage><pages>258-261</pages><issn>1389-9457</issn><eissn>1878-5506</eissn><abstract>Obstructive sleep apnea (OSA) exacerbates Parkinson's disease (PD) manifestations including cognitive dysfunction. Both OSA and PD have been associated with inflammation. Brain-derived neurotrophic factor (BDNF) has been implicated in cognitive function. We aimed to investigate inflammatory cytokines and BDNF in relation to OSA and PD symptoms. In a prospective observational study, patients with PD underwent overnight polysomnography. Morning serum levels of interleukin (IL)-1β, IL-6, IL-8, TNFα, and BDNF were quantified at baseline (n = 64) and 6 months (n = 38). Outcomes included non-motor and motor standard scores; Montreal Cognitive Assessment (MoCA); and Epworth Sleepiness scale (ESS). Associations were assessed using linear regression, adjusting for age, sex and body mass index. At baseline, IL-6 was associated with the Apnea–Hypopnea Index (β = 0.013, p = 0.03), and the Oxygen Desaturation Index (β = 0.028, p = 0.002). No other associations between cytokines and sleep parameters were found. Motor dysfunction was associated with IL-6 (β = 0.03, p = 0.001). ESS was associated non-significantly with IL-6 (β = 0.04, p = 0.07) and BDNF (β = 555, p = 0.06). At follow-up, change in IL-6 was associated with change in non-motor (β = 0.08, p = 0.007), and motor (β = 0.03, p = 0.001) symptoms. Change in BDNF was associated with change in ESS (β = 1450, p = 0.02). We found an association between IL-6 levels and both OSA severity and PD motor dysfunction. At follow-up, increasing IL-6 correlated with deterioration of motor and non-motor PD symptoms. Increasing BDNF correlated with increasing sleepiness. Further work with a larger sample size is needed, but our results support the hypothesis that OSA-related inflammation plays a role in PD manifestations and progression. •Interleukin-6 (IL-6) was associated with severity of obstructive sleep apnea (OSA) and of motor dysfunction in individuals with Parkinson's disease (PD).•Deterioration of motor and non-motor symptoms over 6 months was associated with increasing IL-6.•Increasing BDNF was associated with increasing daytime sleepiness.•These data support further work to elucidate the impact of OSA and sleep disturbances overall in PD symptomatology and progression.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35228136</pmid><doi>10.1016/j.sleep.2021.11.018</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0001-8250-5915</orcidid><orcidid>https://orcid.org/0000-0003-2232-173X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1389-9457
ispartof Sleep medicine, 2022-02, Vol.90, p.258-261
issn 1389-9457
1878-5506
language eng
recordid cdi_proquest_miscellaneous_2634851778
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects BDNF
Brain-Derived Neurotrophic Factor - blood
Cognition
CPAP
Humans
Inflammation
Obstructive sleep apnea
Parkinson Disease - complications
Parkinson's disease
Polysomnography
Prospective Studies
Sleep Apnea, Obstructive
Sleep disorders
title Inflammatory markers and BDNF in obstructive sleep apnea (OSA) in Parkinson's disease (PD)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T21%3A56%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inflammatory%20markers%20and%20BDNF%20in%20obstructive%20sleep%20apnea%20(OSA)%20in%20Parkinson's%20disease%20(PD)&rft.jtitle=Sleep%20medicine&rft.au=Kaminska,%20M.&rft.date=2022-02&rft.volume=90&rft.spage=258&rft.epage=261&rft.pages=258-261&rft.issn=1389-9457&rft.eissn=1878-5506&rft_id=info:doi/10.1016/j.sleep.2021.11.018&rft_dat=%3Cproquest_cross%3E2634851778%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2634851778&rft_id=info:pmid/35228136&rft_els_id=S1389945722000442&rfr_iscdi=true